Biotechnology News and Research

RSS

Medco enters definitive merger agreement with Express Scripts

Express Scripts, Inc. and Medco Health Solutions, Inc. today announced that they have entered into a definitive merger agreement.

21 Jul 2011

PAREXEL completes 100th Asian ethnobridging study

PAREXEL International Corporation, a leading global biopharmaceutical services provider, announced today that it has achieved a significant milestone by completing its 100th Asian ethnobridging study, which is designed to help biopharmaceutical companies accelerate development for the Asia/Pacific market.

From Parexel 21 Jul 2011

Alexion second quarter net product sales of Soliris increase to $185.7 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three and six months ended June 30, 2011. Alexion Pharmaceuticals, Inc. reported net product sales of Soliris of $185.7 million in Q2, reflecting steady addition of new patients, compared to $125.8 million for the same period in 2010.

21 Jul 2011

Medco second-quarter total net revenues increase 4.1% to record $17.1 billion

Medco Health Solutions, Inc. today reported second-quarter 2011 GAAP diluted EPS of $0.85, up 10.4 percent compared to $0.77 for the second quarter of 2010. Adjusting for all amortization of intangible assets, second-quarter 2011 diluted earnings per share increased 10.3 percent to $0.96, up from $0.87 in the second quarter of 2010.

21 Jul 2011

WHO warning increases opportunity for Biomagnetics urine based TB assay

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced that the World Health Organization ("WHO") on Sunday July 17, 2011 warned that the widely used blood tests to detect tuberculosis ("TB") are unreliable and "dangerous" to patients because they produce too many false negatives and positives.

21 Jul 2011

Clinical study of anti-HIV antibody made from genetically modified tobacco plants

Pharmaceuticals can be produced by plants. Antibodies that have been produced in tobacco plants will now for the first time be tested in a clinical study.

21 Jul 2011

Lonza, Cellectis reach milestone in development of newly bioengineered cell line

Cellectis bioresearch, the genome customization specialist and a commercial subsidiary of Cellectis, and Lonza, a world leader in biotechnology production, announce today that they have reached a significant milestone in the development of a newly bioengineered cell line.

21 Jul 2011

Excess brain activity in aMCI patients contributes to brain dysfunction underlying memory loss

An existing anti-seizure drug improves memory and brain function in adults with a form of cognitive impairment that often leads to full-blown Alzheimer's disease, a Johns Hopkins University study has found.

21 Jul 2011

New rapid test accurately distinguishes bacterial and viral infections

Researchers at Ben-Gurion University of the Negev (BGU) have developed a new test that quickly and accurately distinguishes between bacterial and viral infections in as little as five hours.

21 Jul 2011

Researchers influence activity of nerve cells with laser light

Unlike conventional methods, with the so-called optogenetics, the researchers are able to target one cell type. "We are now going to use this method to find out exactly what goes wrong in the nerve cells in movement disorders such as ataxias", said Prof. Dr. Stefan Herlitze.

21 Jul 2011

USPTO issues patent for Mirna's tumor suppressor microRNAs

Mirna Therapeutics, Inc. announced today that the United States Patent and Trademark Office has allowed multiple patent claims related to the therapeutic application of several tumor suppressor microRNAs.

21 Jul 2011

SuperGen closes acquisition of Astex

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced it has closed the transaction to acquire Astex Therapeutics Limited, a privately held, UK-based biotechnology company developing targeted therapies.

21 Jul 2011

USPTO issues patent for Avila's targeted covalent drugs portfolio

Avila Therapeutics, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced today that the United States Patent and Trademark Office has issued Patent No. 7,982,036, "4,6-Disubstituted Pyrimidines Useful as Kinase Inhibitors."

21 Jul 2011

MDL announces HPV-16 Status reflex test

Medical Diagnostic Laboratories, L.L.C. (MDL) is a CLIA certified infectious disease laboratory which specializes in high-complexity, state-of-the-art, automated DNA-based molecular analyses.

20 Jul 2011

ICON second quarter net revenue increases 4.2% to $233 million

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the second quarter ended June 30, 2011.

20 Jul 2011

New report: Global cardiac catheters market to reach US$2.1B by 2015

The global cardiac catheters market is forecast to reach US$2.1 billion by 2015 at a CAGR of 12.9% during the analysis period 2009-2015, according to a new report available on companiesandmarkets.com.

20 Jul 2011

Altogen Labs introduces pyrosequencing services for hospitals, research institutions

Altogen Labs, a biology contract research organization and provider of pre-clinical research services, announced its launch of a pyrosequencing service today.

20 Jul 2011

Sigma introduces CompoZr Targeted Integration Kit – mRosa26

Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich Corporation today announced the launch of CompoZr Targeted Integration Kit – mRosa26, which can precisely and rapidly integrate transgenes into the mouse genome at the Rosa26 safe harbor locus.

19 Jul 2011

EPA to expand Cooperative Research And Development Agreement with NanoLogix

NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today the U.S. Environmental Protection Agency (EPA) intends to expand its Cooperative Research And Development Agreement (CRADA) with NanoLogix to include additional water-borne pathogens.

19 Jul 2011

Convergence initiates CNV1014802 Phase II study in lumbosacral radiculopathy

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announces that the Phase II proof of concept study with CNV1014802 for treating pain associated with lumbosacral radiculopathy (LSR) has started.

19 Jul 2011